TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00573105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Ventral hernia repair by heavy weight mesh
Description: Laparoscopic Ventral hernia repair by heavy weight mesh

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Ventral hernia repair by lighter weight mesh
Description: Laparoscopic Ventral hernia repair by lighter weight mesh
Study: NCT01079806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
Study: NCT01005615

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-FES Upper Extremity Exercise
Description: While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RT300-SLSA, from Restorative Therapies, Inc.
Description: They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
Study: NCT02509715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative nerve monitoring
Description: Intraoperative nerve monitoring during thyroid surgery
Study: NCT02554006

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: good clinical practice
Description: education from physician regarding dual antiplatelet therapy as part of the routine discharge process
Study: NCT03916198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotides
Description: Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
Study: NCT02554006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bundle group
Description: visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
Study: NCT03427762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups.
Study: NCT02133144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overeating fat

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overeating fat

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overeating carbohydrate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overeating carbohydrate
Study: NCT03575780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 Ointment 1%
Description: The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
Study: NCT03592134

Intervention type: OTHER
Intervention: esophageal pressure measurement
Description: Measurement of esophageal pressure to determine the optimal non invasive respiratory support
Study: NCT02652572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granexin
Description: Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
Study: NCT04205474

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: graded bicycle test
Description: the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: graded bicycle test
Description: the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
Study: NCT00866606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benefix
Description: BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
Study: NCT03032523

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard of care glucose test
Description: If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
Study: NCT05093361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty for the treatment of hip arthritis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Self-driven training according to the training plan instructed by physical therapist.
Study: NCT03769961

Intervention type: OTHER
Intervention: No intervention
Description: No interventions - Observational study

Intervention type: OTHER
Intervention: No intervention
Description: No interventions - Observational study

Intervention type: OTHER
Intervention: No intervention
Description: No interventions - Observational study

Intervention type: OTHER
Intervention: No intervention
Description: No interventions - Observational study
Study: NCT01049165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 5 mg, Single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 20 mg, Single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 60 mg, Single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 150 mg, Single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 300 mg, Single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 600 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [14C] BMS-813160
Description: Oral Solution, Oral, 150 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 1200 mg, Single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 2000 mg, Single Dose, 1 day
Study: NCT04285866

Intervention type: DRUG
Intervention: Durvalumab
Description: Durvalumab after chemoradiotherapy
Study: NCT05333172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task exercises
Description: Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual task exercises
Description: Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
Study: NCT00091130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HspE7
Description: Given SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02190357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
Study: NCT04225936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Single Dose
Study: NCT00068250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation therapy temozolomide
Description: Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation therapy temozolomide
Description: Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
Study: NCT04620382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Midodrine 5-10 mg, single oral dose
Study: NCT04225936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Single Dose
Study: NCT04620382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: single oral dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal compression
Description: abdominal compression up to 40 mmHg during head-up tilt

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham compression
Description: Sham abdominal compression during head-up tilt
Study: NCT01044212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docusate
Description: Docusate 100mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel medications
Description: Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
Study: NCT03263923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention and journaling
Description: Cognitive behavioral skills training and 4 weeks of online journaling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reflective journaling
Description: Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling
Study: NCT02567682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
Study: NCT01245881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional photothermolysis laser
Description: * Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: broad-spectrum sunblock (SPF 50+)
Study: NCT01057225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study: NCT02062892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
Study: NCT02056665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MINOCYCLINE
Description: Pill Minocycline 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MINOCYCLINE
Description: Pill Minocycline 50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MINOCYCLINE
Description: Pill Minocycline 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO (for Minocycline)
Description: Pill manufactured to mimic Minocycline 50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO (for Minocycline)
Description: Pill manufactured to mimic Minocycline 50 mg capsule
Study: NCT00969761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-6727
Description: Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
Study: NCT01443650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT00969761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: low to high dose
Study: NCT02181361

Intervention type: DRUG
Intervention: hirudin plus aspirin
Description: natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily

Intervention type: DRUG
Intervention: Warfarin
Description: an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
Study: NCT01643850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
Study: NCT00992381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: 500mg Naproxen and 20mg esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn
Description: 500mg Naproxen
Study: NCT03376776

Intervention type: PROCEDURE
Intervention: Vitrectomy

Intervention type: PROCEDURE
Intervention: Vitrectomy
Study: NCT01071941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: administration of rRp450 into the hepatic artery
Description: Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
Study: NCT01571284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFLIBERCEPT AVE0005
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: irinotecan, 5-FU and leucovorin
Study: NCT01010568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab and Bendamustine
Description: Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
Study: NCT01719029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate/Higher Fat Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate/Low fat diet
Study: NCT03510468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Each tablet contains 25 mg of tenofovir alafenamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Each tablet is formulated as 100 or 300 mg of isoniazid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: Each tablet contains 50 mg of pyridoxine
Study: NCT04911400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper-lower clear plastic retainers + Class III elastics
Description: Addition of Class III elastics to clear plastic retainers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper-lower clear plastic retainers
Description: Upper-lower clear plastic retainers
Study: NCT02788773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study: NCT04533360

Intervention type: DIAGNOSTIC_TEST
Intervention: VITROS Anti-SARS-CoV-2 IgG test
Description: The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.

Intervention type: DIAGNOSTIC_TEST
Intervention: VITROS Anti-SARS-CoV-2 IgG test
Description: The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.

Intervention type: DIAGNOSTIC_TEST
Intervention: VITROS Anti-SARS-CoV-2 IgG test
Description: The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.

Intervention type: DIAGNOSTIC_TEST
Intervention: VITROS Anti-SARS-CoV-2 IgG test
Description: The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
Study: NCT02622802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
Study: NCT03995680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
Study: NCT00613249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Gel 4750, 0.05%, 2.5g
Description: intravaginal gel, dosed daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Gel 4789, 0.05%, 2.5g
Description: intravaginal gel, dosed daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC-based Placebo Gel
Description: intravaginal gel, dosed daily
Study: NCT03386682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESTYME® MATRIX Breast Implants
Description: Breast implant surgery in breast reconstruction or breast augmentation